Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 22Stomach Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1MSS Metastatic Colorectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Bevacizumab 7Cetuximab 3Oxaliplatin 2Fluorouracil 2Capecitabine 2trifluridine tipiracil drug combination 1sintilimab 1irinotecan sucrosofate 1folfirinox 1balstilimab 1anisodamine 1Vemurafenib 1Sirtuins 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Liver Transplantation 1Leucovorin 1Irinotecan 1HMPL-013 1Folfox protocol 1Doxorubicin 1Dexamethasone 12-(phenylmethyl)-1-naphthol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Cancer Metastatic × HMPL-013 × Clear all
NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡